Details of the Drug
General Information of Drug (ID: DM7MUZ1)
Drug Name |
2-Hydroxymethyl-Pyrrolidine-3,4-Diol
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-(Hydroxymethyl)-[2R-(2a,3b,4b)]-3,4-Pyrrolidinediol; 2-(Hydroxymethyl)-(2R-(2a,3b,4b))-3,4-Pyrrolidinediol; ACMC-20m9e3; ACMC-20m1d3; ACMC-20m9e4; 3,4-Pyrrolidinediol,2-(hydroxymethyl)-, (2S,3S,4R)-; 3,4-Pyrrolidinediol,2-(hydroxymethyl)-, (2R,3R,4S)-; AC1L1B8Z; 3,4-Pyrrolidinediol, 2-(hydroxymethyl)-, (2R,3S,4S)-; SCHEMBL981088; CTK8A3364; 1,4-dideoxy-1,4-iminopentitol; OQEBIHBLFRADNM-UHFFFAOYSA-N; HMS3373I18; IMR; 97058-12-3
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure |
![]() |
||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 133.15 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -1.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||